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Abstract
Purpose Patients with cancer frequently experience
chemotherapy-induced anaemia (CIA) and iron deficiency.
Erythropoiesis-stimulating agents (ESAs), iron supplementa-
tion and blood transfusions are available therapies. This study
evaluated routine practice in CIA management.
Methods Medical oncologists and/or haematologists from
nine European countries (n=375) were surveyed on their last
five cancer patients treated for CIA (n=1,730). Information
was collected on tests performed at diagnosis of anaemia,
levels of haemoglobin (Hb), serum ferritin and transferrin
saturation (TSAT), as well as applied anaemia therapies.
Results Diagnostic tests and therapies for CIA varied across
Europe. Anaemia and iron status were mainly assessed by Hb
(94 %) and ferritin (48 %) measurements. TSAT was only
tested in 14%. At anaemia diagnosis, 74% of patients had Hb
≤10 g/dL, including 15 % with severe anaemia (Hb <8 g/dL).
Low-iron levels (ferritin ≤100 ng/mL) were detected in 42 %
of evaluated patients. ESAwas used in 63% of patients, blood
transfusions in 52 % and iron supplementation in 31 % (74 %
oral, 26 % intravenous iron). Only 30 % of ESA-treated
patients received a combination of ESA and iron supplemen-
tation. Blood transfusions formed part of a regular anaemia
treatment regimen in 76 % of transfused patients. Manage-
ment practices were similar in 2009 and 2011.
Conclusion Management of anaemia and iron status in pa-
tients treated for CIA varies substantially across Europe. Iron
status is only assessed in half of the patients. In contrast to
clinical evidence, iron treatment is underutilised and mainly
based on oral iron supplementation. Implementation of guide-
lines needs to be increased to minimize the use of blood
transfusions.
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Introduction
Patients with cancer frequently experience chemotherapy-
induced or cancer-related anaemia and iron deficiency (ID)
[1, 2]. Anaemia adds a substantial burden to these patients
already affected by cancer and its treatment [1–3]. ID is a
major component in the pathogenesis of anaemia in cancer
patients [4] and has been estimated to affect 19–63 % of
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patients with different tumour types [5]. The prevalence of ID
increases with progression of the disease and correlates with
the prevalence of anaemia [2].
Impaired iron homeostasis (a common feature in chronic
disease), chronic blood loss and nutritional deficiencies (e.g.
cancer-induced anorexia) are the main causes of ID in cancer
patients [5]. Early diagnosis and management of ID is impor-
tant to reduce the risk of anaemia and improve patient care.
Biological iron status markers include serum ferritin, which
reflects storage iron under non-inflammatory conditions, and
transferrin saturation (TSAT), reflecting circulating iron that is
available for erythropoiesis. A low TSAT is related to both
absolute and functional iron deficiency [6]. In absolute ID,
iron stores are depleted (serum ferritin ≤100 ng/mL in patients
with inflammation, including cancer) [5, 6]. Functional ID is
characterised by a lack of available iron (TSAT ≤20%) despite
normal or elevated serum ferritin [5–7]. Most iron-deficient
cancer patients present with functional ID [2].
Historically, anaemia in cancer patients was treated with
red blood cell (RBC) transfusions or erythropoiesis-
stimulating agents (ESAs). However, a substantial proportion
of anaemic cancer patients remain unresponsive to ESA treat-
ment [8–10], and over recent years, evidence has accumulated
that RBC transfusions, as well as ESA use outside the current
label and guidelines, can increase all-cause mortality [11–13].
Current guidelines therefore recommend preventing RBC
transfusions and using ESAs with the lowest effective dose
and in approved indications only [14–20].
In ESA-treated patients with functional ID, concomitant
administration of intravenous (i.v.) iron should be considered
[14]. Several controlled clinical trials have shown that i.v. iron
supplementation of ESA therapy enhances haematological
response and may be effective in reducing ESA doses and
transfusion requirements [21–26]. In contrast, administration
of oral iron showed less or no effect in comparative trials [21,
25].
This cross-sectional study evaluated the routine practice in
the diagnosis and treatment of anaemia and ID in patients with
chemotherapy-induced anaemia (CIA) and the implementa-




Oncologist, haematologist and onco-haematologist (manag-
ing mainly solid or mainly haematological tumours), in the
manuscript collectively referred to asmedical oncologists and/
or haematologists, were selected at random from nine Euro-
pean countries. They reported data on their last five cancer
patients treated for CIA within the preceding 6 months.
Patients who had not received any chemotherapy in the last
3 months and patients with myelodysplastic syndromes were
excluded. Eligible medical oncologists and/or haematologists
had to spend >50 % of their working time on patient care and
personally see and treat more than five cancer patients with
CIA per month.
Details on patients were collected from patient records in
two surveys: from June to September 2009 in France (FR),
Germany (DE), Spain (ES), Switzerland (CH) and United
Kingdom (UK) (survey 1) and from August to September
2010 in Austria (AT), Italy (IT), the Netherlands (NL) and
Sweden (SE) (survey 2).
An additional data set was collected in survey 1 countries
about 2 years after the first survey (June to August 2011). This
data set was only used for comparison with the corresponding
data set from 2009, to assess potential changes in routine
practice over time. It was not included in the main analysis.
Data collected in patient record forms
Collected patient demographics included gender, age, weight,
height, dietary habits, comorbidities, type and TNM stage of
cancer. Data on anaemia management included a list of hae-
matological tests performed at diagnosis of anaemia, levels of
Hb and iron status parameters (serum ferritin, TSAT) and
prescribed anaemia treatment. For all iron-treated patients,
information on the iron administration route (oral, i.v., intra-
muscular) and the type of specialist that initiated the treatment
were collected. Additional details, which were recorded dur-
ing survey 1 only, included reasons for prescription of i.v. or
oral iron as well as anaemia-related symptoms. In survey 2,
RBC transfusions were evaluated in more detail.
Some questions were stated in a slightly different way in
survey 2 to avoid ambiguity that had been observed among
responses to these questions in the first survey and to better
reflect the time frames physicians referred to when asked for
given treatments. The question for “current” anaemia treat-
ment (survey 1) was extended to “current or last treatment” in
survey 2, and the question on whether a patient had “ever”
received an RBC transfusion (survey 1) was limited to “during
the last 12 months” in survey 2.
Data collected in physician self-reporting section
In survey 1, participating medical oncologists and/or
haematologists were asked to disclose the trigger points (Hb
levels) they used for starting treatment in male/female patients
and minimal target Hb levels.
Data analysis
Results are presented for all nine countries combined and as
range of overall data in the individual countries (shown in
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square brackets). Alternatively, data from survey 1 or survey 2
countries only were combined, as indicated. Patients without
current anaemia treatment (only in survey 1) were excluded
from the analysis for better comparability of the results of the
two surveys. Collected data were verified by plausibility
checks and phone interviews of 10 % of participants.
Due to the low number of patients receiving i.v. iron,
information on the reasons for prescribing i.v. iron was gath-
ered from an extended patient sample, for which each partic-
ipating physician provided data from up to two additional i.v.
iron-treated patients. The extended patient sample was not
used in any of the other analyses.
Results
Baseline patient characteristics
In total, 375 medical oncologists and/or haematologists were
recruited of whom 321 were hospital-based and 54 were, at
least partially, office-based. Details on a total of 1,860 patients
with CIA were collected. After excluding patients with no
current anaemia treatment, 1,730 patients were included in
the analysis (Table 1). Patients had a variety of haematological
and solid malignancies and 46 % had metastatic disease.
Assessment of anaemia and iron status in cancer patients
with CIA
Diagnosis of anaemia was according to local definition and
performed or confirmed by assessment of Hb levels in 94 %
[86–99%] of the study population (Fig. 1a). The proportion of
patients with Hb measurements was slightly higher in at least
partially office-based vs. hospital-based medical oncologists
and/or haematologists (96.7 vs. 93.5 %; p=0.05). Median Hb
at diagnosis of anaemia was 9.1 g/dL (range median levels
across countries, [9.0–9.6 g/dL]; Table 1). Of the patients
tested for Hb, 26 % [14–40 %] presented with mild (Hb
≥10 g/dL), 59 % [49–68 %] with moderate (Hb ≤9.9 and
≥8.0 g/dL) and 15 % [9–24 %] with severe anaemia (Hb
<8 g/dL; Fig. 1b). Other tests performed were haematocrit
(76 % [47–97 %]) and RBC indices.
Assessment of iron status was mainly based on serum
ferritin measurements (48 % [23–60 %]; Fig. 1a). The propor-
tion of patients with serum ferritin assessment was significant-
ly higher among office-based vs. entirely hospital-based med-
ical oncologists and/or haematologists (60.8 vs. 45.3 %; p=
0.001). Median ferritin at initial diagnosis was 150 ng/mL
[50–243 ng/mL] (Table 1). Serum ferritin levels were low
(≤100 ng/mL) in 42 % [21–65 %] of tested patients, and
22 % [8–41 %] even had ferritin ≤30 ng/mL (Fig. 1b). TSAT
was only tested in a small percentage (14 % [2–25 %];
Fig. 1a). Median TSAT of tested patients was 29 % [15–
35 %] (Table 1), and over a quarter of tested patients (27 %
[7–100 %]) had a TSAT ≤20 %, reflecting low amounts of
circulating iron (Fig. 1b). The wide variation of TSAT values
between the countries is probably due to the small number of
tested patients. The rates of TSAT assessment were compara-
ble for hospital-based and office-based medical oncologists
and/or haematologists (16.3 vs. 13.3 %).
Treatment of anaemia and iron deficiency
ESAwas the most common anaemia treatment in the evaluat-
ed population. It was used in 63 % [15–100 %] of patients
either alone or in combination with other anaemia treatments
(Fig.2a). In 23 % [9–46 %], anaemia treatment included both
ESAs and RBC transfusions. In total, RBC transfusions were
administered to more than half of all patients (52 % [11–
93 %]) at some stage (survey 1) or during the last 12 months
(survey 2). RBC transfusions were more frequently adminis-
tered by hospital-based than office-based medical oncologists
and/or haematologists (53.9 vs. 43.3 %; p=0.005). About a
third of all patients (31 % [11–61 %]) received iron as current
or last treatment. Overall, there was substantial variability
across countries for all three treatment options.
Among iron-treated patients, the majority received an oral
iron product (74 %) and only 26% [4–77 %] received i.v. iron
(Fig.2b). Switzerland was the only country where the majority
of iron-treated patients received i.v. iron (77 %). The propor-
tion of patients receiving i.v. iron was higher among office-
based than hospital-based medical oncologists and/or
haematologists (15.9 vs. 7.5 %; p=0.001). A small percentage
of iron-treated patients received iron supplementation as
monotherapy without concomitant ESA or RBC transfusion
(17 % oral and 5 % i.v. iron). Of note, only 30 % of ESA-
treated patients received iron supplementation and among
these, the majority (70 %) received oral iron.
Use of iron therapy in survey 1 patients (FR, DE, ES, CH, UK)
In survey 1 countries, further details on iron therapy were
surveyed and analysed. On average, 67% of first prescriptions
were for an oral iron formulation. In the UK, oral iron even
accounted for all first prescriptions. Conversely, in Switzer-
land, 77 % of first prescriptions were for an i.v. iron formula-
tion. At commencement of iron therapy, mean Hb, ferritin and
TSAT levels were 9.2 g/dL [8.6–9.3 g/dL], 120 ng/mL [59–
187 ng/mL] and 26 % [15–32 %], respectively. A comparison
of “current” vs. “previous” iron treatment revealed that the
iron administration route was rarely switched in individual
patients (overall only in 6 % of iron-treated patients). Most
commonly (in 56 % of cases where there was a change), the
switch was made from oral to i.v. iron.
Reasons for iron treatment selection were analysed in the
extended patient sample. “Quick onset of action”was stated as
Support Care Cancer (2014) 22:2197–2206 2199
the main reason (37 %) for selecting i.v. iron, whereas conve-
nience rather than efficacy-related arguments were the main
basis for using oral iron (“easy/convenient administration”
(54 %), “familiarity” (46 %)). In 30 % of cases, use of oral
iron was justified by “effective when used in combination”.
Iron treatment was mainly initiated by medical oncologists
and/or haematologists (98 % of i.v. and 91 % of oral iron
treatments). In the UK, a notable minority of patients (17 %)
received oral iron prescribed by general practitioners.
Mean self-reported Hb cut-off levels, at which surveyed
medical oncologists and/or haematologists would initiate any
kind of anaemia treatment, were 9.6 g/dL [9.0–10.2 g/dL] for
male and 9.4 g/dL [8.8–10.0 g/dL] for female patients. Mean
target Hb levels were 11.1 g/dL [10.1–11.7 g/dL] and 10.9 g/
dL [9.9–11.6 g/dL] for male and female patients, respectively.
The most frequent anaemia signs and symptoms were
fatigue, weakness, paleness and breathlessness, and there
was a trend for a decrease in the proportion of symptomatic
patients after iron treatment (fatigue, 71 to 64%; weakness, 67
to 51 %; paleness, 51 to 36 %; breathlessness, 39 to 30 %).
The proportion of patients being completely free of anaemia
symptoms increased from 5 to 17 %.
Use of RBC in survey 2 patients (AT, IT, NL, SE)
Detailed questions regarding the use of RBC transfusions
were asked during survey 2. In the majority (76 %) of RBC-
treated patients, transfusions formed part of a regular treat-
ment regimen (vs. being an emergency administration due to a
rapid drop in Hb). In 45% [26–53%] of RBC-treated patients,
transfusions were given at a ≤3-month interval and 3 % re-
ceived transfusions every week or even more frequently.
Among the options in the questionnaire, “easily available”
(47 % [15–68 %]) and “uncomplicated procedure” (34 % [0–
52 %]) were the most commonly selected reasons for admin-
istration of RBC transfusions. Further reasons were that the
Table. 1 Baseline patient characteristics and number of medical oncologists and/or haematologists by country
FR DE ES CH UK AT IT NL SE Total/mean
Medical oncologists and/or
haematologists (n)
51 57 52 33 55 24 51 25 31 375
Patients (n) 237 262 228 135 217 119 254 124 154 1,730
Patient demographics
Male (%) 57 55 60 56 57 52 55 53 53 56
Age (years; mean) 61 62 61 58 58 59 61 61 65 61
Type of cancer (≥10 % each) and metastatic stage
Lymphoma (%) 27 18 26 24 17 13 21 10 26 21
Lung (%) 10 21 15 13 7 14 18 13 1 13
Breast (%) 12 15 9 10 10 19 17 18 9 13
Myeloma (%) 10 9 16 4 17 5 11 14 23 12
Colorectal (%) 8 11 7 6 10 16 11 8 11 10
Stage IV (%) (any T, any N, M1) 52 53 40 52 48 60 30 55 39 46
Hb levels and iron status at diagnosis
Hb (g/dL)
median 9.0 9.1 9.5 9.6 9.0 9.0 9.0 9.4 9.2 9.1
range 4.0–14.7 6.1–14.7 6.0–12.3 2.8–13.3 5.0–13.5 4.0–12.5 5.9–13.0 7.0–12.0 5.4–14.0 2.8–14.7
(n) (231) (260) (202) (132) (214) (109) (225) (119) (133) (1,625)
Ferritin (ng/mL)
median 215 237 127 150 100 243 50 65 99 150
range 2–927 2–999b 5–999b 4–999b 4–632 5–999b 2–999b 5–452 2–999b 2–999b
(n) (128) (158) (137) (78) (80) (50) (124) (31) (35) (821)
TSAT (%)a
median 30 28 26 18 22 15 35 15 30 29
range 7–75 5–70 6–90 16–20 8–71 2–45 10–70 12–16 10–99 2–99
(n) (47) (25) (58) (3) (25) (17) (54) (3) (5) (237)
FR France,DEGermany, ES Spain,CH Switzerland,UKUnited Kingdom, ATAustria, IT Italy,NL the Netherlands, SE Sweden,Hb haemoglobin, TSAT
transferrin saturation
a Small sample sizes due to low number of tested patients
b ≥999 ng/mL (entry cut-off of the survey)
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anaemia was not controlled by ESAs alone (29 % [14–69 %])
or by the given iron treatment (24 % [0–39 %]).
Potential changes in anaemia management from 2009 to 2011
Two years after the first study, the survey was repeated and
710 new cases of CIAwere reported by 142 medical oncolo-
gists and/or haematologists. The patient population analysed
in this follow-up survey was comparable to the one of the
initial survey, with a similar gender and age distribution, and
similar disease profile. The majority (85 %) of the surveyed
medical oncologists and/or haematologists were hospital-
based and 15 % were, at least partially, office-based.
As in the initial survey, anaemia and iron status were
mainly assessed by measurement of Hb and serum ferritin
(Table 2). Hb as a diagnostic test was slightly more frequently
used in the second survey (98 vs. 89 %), while the frequency
of serum ferritin tests was almost the same as in 2009 (49 vs.
48 %). A slight improvement was seen in the utilisation of
TSAT, the use of which nearly doubled in 2011 (23 % [14–
39 %] vs. 13 % [4–23 %]) but still remained low compared to
ferritin tests. Median values for Hb, serum ferritin and TSAT
at diagnosis of anaemia were similar or slightly lower in the
follow-up survey, and the percentage of patients presenting
with severe anaemia (Hb <8 g/dL) was higher (25 vs. 15 %).
Slightly more evaluable CIA patients were iron-deficient at
diagnosis of anaemia (serum ferritin ≤30 ng/mL, 27 vs. 17 %;
serum ferritin ≤100 ng/mL, 50 vs. 36 %; TSAT ≤20 %, 39 vs.
29 %). Thirty-one percent of patients received iron therapy
(vs. 24 % in 2009), and the majority of these received oral
iron. Compared to 2009, slightly more iron-treated patients
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Fig. 1 a Diagnostic tests used to
assess anaemia and iron status in
cancer patients with CIA. Hb
haemoglobin, TSAT transferrin
saturation. b Proportion of
anaemic cancer patients with low
levels of haematological
parameters at diagnosis of
anaemia. Hb haemoglobin, TSAT
transferrin saturation
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Discussion
This study on cancer patients treated for CIA revealed sub-
stantial variations in routine diagnosis and treatment ap-
proaches across Europe. A high proportion of patients had
moderate to severe anaemia (Hb ≤10 g/dL) and a considerable
percentage presented with ID (ferritin ≤100 ng/mL or TSAT
≤20 %) at the time of diagnosis of anaemia. The most com-
monly used anaemia therapy was administration of an ESA
but also RBC transfusions were frequently given. About a
third of patients received iron supplementation but only a
minority of iron-treated patients received i.v. iron, despite
clinical evidence for its efficacy [21–26] and recommenda-
tions in guidelines to consider its use [5, 14, 15, 17–19].
While current treatment guidelines recommend baseline
and periodic assessment of iron status [5, 16, 20], at least a
third of patients in this study had no iron status assessed at
diagnosis of anaemia. If assessed, diagnosis was mainly based
on serum ferritin measurements whereas TSATwas underused
as a diagnostic marker. Ferritin is an acute phase protein and
often does not accurately reflect iron stores in cancer patients.
Although TSAT is to some extend also affected by inflamma-
tory cytokines, it is accepted as a relevant marker of ID and a
TSAT value <20 % is a feature of both absolute and functional
ID [5].
The survey data demonstrate that the management of ID in
patients with CIA continues to rely on oral iron preparations.
Also in the subgroup of ESA-treated patients, concomitant iron
supplementation consisted mainly of oral iron. Although oral
iron may be used in cancer patients with absolute ID who do
not receive any ESA and do not have active inflammation [14],












































Fig. 2 a Treatments used for
CIA. *Patients who received
RBC transfusions at some stage
(survey 1) or during the last
12 months (survey 2); †current
(survey 1) or last (survey 2)
treatment. RBC red blood cells,
ESA erythropoiesis-stimulating
agents. b Administration routes
used for iron therapy; †current
(survey 1) or last (survey 2)
treatment received
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oral iron in iron-deficient patients scheduled for initial or
ongoing ESA-treatment (Table 3) [14, 15, 17–19]. Intravenous
iron supplementation resulted in increased haematological re-
sponse, reduced need for transfusions and faster correction of
anaemia [21–28]. In contrast, oral iron did not improve re-
sponse vs. no iron in ESA-treated cancer patients [21, 25]. Side
effects were similar in study treatment groups, confirming that
only very few clinically relevant adverse events are observed
with the new formulations of i.v. iron [29, 30]. Good tolerabil-
ity of i.v. iron has been shown not only in cancer patients [5]
but also in other patient populations with chronic conditions,
such as chronic heart failure (FAIR-HF) [31] or chronic kidney
disease [32]. Since cancer patients frequently present with
multiple comorbidities and cancer therapies are often cardio-
and/or nephrotoxic, these are important considerations [33].
Interestingly, 22 % of iron-treated patients in this study
received iron as monotherapy (5 % i.v.; 17 % oral). Data from
a recently published large prospective observational study
indicate that i.v. iron as sole therapy of anaemia in cancer
can increase Hb levels even without concomitant ESA [35].
This data is supported by the results of four smaller
randomised studies [36–39], yet further studies are warranted.
More than half of all patients in this study received RBC
transfusions. Further inquiries revealed that transfusions were
given on a regular basis, and not only as rescue therapy, possibly
reflecting suboptimal results obtained with ESA alone or in
combination with oral iron. The frequent use of transfusions in
patients with CIA is surprising, considering the health risks
associated with this treatment. Possible complications of RBC
transfusions include transfusion reactions, alloimmunisation,
transfusion-related acute lung injury (TRALI), transfusion-
associated circulatory overload (TACO), increased risk of infec-
tions, thromboembolic complications and transfusion-
transmitted infections [12, 40]. Although safety measures have
reduced the incidence of transfusion-transmitted HIV, HCVand
HBV infections, newly emerging and several re-emerging path-
ogens that are currently not tested for remain a risk [41]. Inmany
studies, an adverse clinical outcome (higher local tumour recur-
rence rate or shorter survival time) has been shown for cancer
Table. 2 Anaemia treatment practice change over time in survey 1 countries
2009 2011
N=1,209 N=710
Used diagnostic tests (%)a
Hb 89 [85–95] 98 [96–100]
Ferritin 48 [32–56] 49 [37–58]
TSAT 13 [4–23] 23 [14–39]
Hb and iron status at initial diagnosis of anaemia
Median Hb (g/dL) 9.0 [8.9–9.6] 8.8 [8.1–9.2]
Median ferritin (ng/mL) 165 [100–237] 100 [45–121]
Median TSAT (%) 28 [18–30] 25 [15–34]
% below cut-offsb
Hb ≤10 g/dL 72 [61–82] 86 [76–90]
Hb <8 g/dL 15 [9–22] 25 [18–36]
Ferritin ≤100 ng/mL 36 [21–49] 50 [31–74]
Ferritin ≤30 ng/mL 17 [8–21] 27 [13–43]
TSAT ≤20 % 29 [18–60] 39 [15–63]
Used treatment options (%)c
Iron therapy 24 [9–55] 31 [20–49]
Among iron-treated patients
– Iron monotherapy 23 [10–40] 30 [10–59]
– Iron+ESA and/or RBC 77 [60–90] 70 [44–90]
– Oral iron 67 [22–100] 60 [8–87]
– i.v. iron 33 [0–78] 40 [13–92]
ESA 47 [13–81] 45 [19–88]
RBC 54 [27–80] 56 [32–83]
ESA+RBC 15 [4–26] 12 [5–19]
Data shown for all countries combined and range across countries; Hb
haemoglobin, TSAT transferrin saturation,ESA erythropoiesis-stimulating
agent, RBC red blood cell
a% of all patients
b% of tested patients
c% of treated patients
Table. 3 Randomised controlled trials on i.v. iron compared to oral or no
iron supplementation of ESAs in cancer patients
Study Treatment arm Response rate a (%)
Auerbach 2004 [21] i.v. iron 68*
oral iron 36
no iron 25
Hedenus 2007 [24] i.v. iron 87*
no iron 53
Henry 2007 [25] i.v. iron 53*
oral iron 36
no iron 36
Bastit 2008 [23] i.v. iron 86*
standard 73
Pedrazzoli 2008 [26] i.v. iron 77*
no iron 62
Auerbach 2010 [22] i.v. iron 82*
no iron 63
Steensma 2011 [33, 34] i.v. iron 70 (80 %)b
oral iron 67
no iron 65
Beguin 2013 [28] i.v. iron 100*
no iron 79
*p<0.05 vs. no iron (and oral iron if tested); response rates for oral iron
were not significantly different vs. no iron in any of the studies with an
oral iron treatment arm
a Response was defined as either Hb increase ≥2 g/dL, Hb ≥11 g/dL, Hb
≥12 g/dL or Hb ≥13 g/dL in the different studies
b Patients who received at least 750 mg iron [34]
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patients receiving transfusions [13]. In addition, there are several
procedural problems associated with RBCs (e.g. transfusion of
RBC to ABO-incompatible recipients, availability of sufficient
blood donations and quality issues). Guidelines therefore rec-
ommend preventing RBC transfusions by timely recognition
and appropriate treatment of anaemia [14–16].
Findings strikingly similar to this study’s were reported in a
retrospective observational study in France (N=276) and a
recent cross-sectional survey in Germany (N=3,867) [42, 43].
Both studies showed frequent use of RBC transfusions in
anaemic cancer patients and disregard of available treatment
options for iron deficiency. Among iron-treated patients, iron
therapy mainly consisted of oral iron. The authors concluded
that routine treatment practice did not reflect current guide-
lines which recommend prevention of RBC transfusions and
the i.v. route for iron supplementation, based on evidence that
oral iron is ineffective in cancer-associated anaemia [21, 25].
Our follow-up survey, 2 years after the first one, revealed
only minor changes in management practices. Notably, there
was an increase in the use of TSAT as a diagnostic marker. In
addition, in year 2011, Hb levels at diagnosis of anaemia were
slightly lower, possibly reflecting a general reservation regard-
ing the use of ESA as a consequence of discussions about its
safety [11]. However, a 2-year interval may not be long
enough for significant changes in management practices.
The majority of patients in this study population had al-
ready reached a moderate or severe stage of anaemia at the
time of anaemia diagnosis. A possible reason for this may be
that diagnostic tests and treatment were only initiated when
anaemia symptoms were noticed.
Some caution is required in generalising the results of this
study. The study was designed to capture diagnosis and treat-
ment of CIA in routine practice in cancer patients who have
already been treated for CIA. Among those, analysis was
limited to the last five patients treated by each participating
physician. Only limited information such as the presence of
comorbidities was obtained, but no detailed data on the clin-
ical history and the specific cause(s) of anaemia were collect-
ed. While the majority of cancer patients undergoing chemo-
therapy become anaemic, the cause of anaemia often is mul-
tifactorial and treatment decisions should be based on its
underlying aetiology. Therefore, iron status should carefully
be assessed, in addition to haemoglobin levels, when use of
iron replacement therapy is considered in CIA patients. The
significant variability in anaemia management observed in
this study may not only reflect differences in appraisal of
treatment benefits and insufficient concordance with treatment
recommendations but also country-specific differences in re-
imbursement policies. The low utilisation of ESAs in the UK
for instance may mainly be due to guidance against ESA use
by the National Institute of Clinical Excellence (NICE).
Although some statistically significant differences in the
use of diagnostic tests and anaemia treatment options were
observed between entirely hospital-based and at least partially
office-based medical oncologists and/or haematologists, these
were of small magnitude, particularly in comparison to inter-
country differences. The wide variation in diagnostic ap-
proaches seen between the countries is one of the main find-
ings of this study, indicating the heterogeneity of patient
management across Europe, and probably also between
centres/practices within individual countries.
Conclusions
This study shows considerable variations in the diagnosis and
therapy of CIA across different European countries. TSAT, a
simple parameter indicating insufficient iron supply, was used
only rarely, while ferritin levels were more frequently obtain-
ed although this parameter is a less reliable marker for iron
status in patients with inflammatory conditions such as cancer.
ID was mainly treated with oral iron while i.v. iron was rarely
used. Information about the i.v. option, that has been shown to
significantly increase the response to ESAs when given con-
comitantly, should be better promoted. More efficient strate-
gies should be developed to minimise the use of blood trans-
fusions and to optimise anaemia management in patients with
cancer. Developing practical tools such as simplified treatment
algorithms may be helpful in clinical management of anaemia
and iron deficiency.
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